Bing

SEARCH HISTORY

Shares of Mylan NV (MYL) slumped 5% in premarket trade Monday, after the drug maker said it began a public offering of 35 million shares of its common stock held by Abbott Laboratories (ABT) . That represents 32% of the 110 million Mylan shares …
news.morningstar.com · 3/30/2015
Pa. (Photo: KEITH SRAKOCIC, AP file) PITTSBURGH — The generic drugmaker Mylan is buying Abbott Laboratories' generic-drugs business in developed markets for stock valued at about $5.3 billion. Stock in Mylan is surging 2.6% on the news in …
USA Today · 7/14/2014
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has just approached Mylan N.V. (NASDAQ: MYL) with a public takeover bid valued at $82 per share in cash and stock. The offering would consist of approximately 50% in cash and 50% in stock. While …
24/7 Wall ST · 4/21/2015
More from Bing News
NEW YORK – Generic drugmaker Mylan is making official its $32 billion-plus offer for over-the-counter medicines maker Perrigo despite opposition from a larger rival that wants to buy Mylan. Perrigo Co. rejected Mylan NV's offer Tuesday, saying it was too ...
Fox Business · 4/24/2015
Perrigo shareholders would receive $205 in a combination of cash and Mylan stock for each Perrigo share, which represents a greater than 25% premium to the Perrigo trading price as of the close of business on Friday, April 3, 2015 (the last trading date ...
The Business Insider · 4/8/2015
Underperformance equals value? Teva, Actavis, and Mylan are all generic drug manufacturers, with Actavis and Mylan's stock easily outperforming Teva during the last five years. ACT data by YCharts The generic drug market as a whole has benefited greatly ...
The Motley Fool · 7/24/2014
This increased stake gives Paulson more leverage in pushing Mylan to broker a deal with the rival. Teva has had a strong year thus far, according to TipRanks seven out of the eight analysts covering the stock rating it a Buy and one rating it a hold.
Investopedia · 6/3/2015
Mylan NV rejected Teva Pharmaceutical Industries Ltd’s unsolicited $40-billion takeover offer on Monday, saying it was too low and calling Teva stock an “unacceptable” currency. Teva, the world’s biggest maker of generic drugs, last week offered $ ...
Globe and Mail · 4/27/2015
The company said it would pay $205 in a combination of cash and Mylan stock for each Perrigo share, which represents a greater than 25% premium to the latter’s stock price as of April 3, 2015. According to Mylan, the marriage of these “highly ...
Pharma Times · 4/8/2015
Earlier this month, Mylan offered to buy Perrigo for $205 per share in cash and stock. Perrigo said Tuesday that previous offer substantially undervalues the company. A new bid from Mylan will include firm financing commitments, and firm commitments to ...
CNBC · 4/22/2015

Mylan

Company
Mylan N.V. is a global generic and specialty pharmaceuticals company registered in the Netherlands and with operational headquarters …
Mylan N.V. is a global generic and specialty pharmaceuticals company registered in the Netherlands and with operational headquarters in Hatfield, Hertfordshire in the United Kingdom. In 2007, Mylan acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients for generic drugs, and the generics business of Germany-based Merck KGaA. Through these acquisitions, Mylan has grown from the third-largest generic and pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world. Mylan now has approximately 22,000 employees, more than 1,000 separate products, and serves customers in more than 150 countries and territories. Mylan has a global manufacturing output of more than 45 billion doses.
Data from: Wikipedia · Freebase